Orkin C, Arasteh K, Hernández-Mora MG, et al. - This study was sought to evaluate the utility and safety of Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. Researchers carried out to perform a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir–abacavir–lamivudine. Individuals who had an HIV-1 RNA level of fewer than 50 copies per milliliter after 16 weeks were allocated randomly in a 1:1 ratio to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary outcome had the percentage of individuals who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm). The outcomes of this research displayed that therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir–abacavir–lamivudine about maintaining HIV-1 suppression. Injection-site reactions were common.